The EEF1A2 Knockout HT29 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal population of HT29 colorectal adenocarcinoma cells engineered to disrupt the EEF1A2 gene, which encodes the eukaryotic translation elongation factor 1 alpha 2 (eEF1A2). This polyclonal knockout pool provides a heterogeneous loss-of-function model that enables the study of EEF1A2-dependent processes in a human colorectal cancer background. The cells are suitable for functional genomics, drug discovery, and mechanistic studies requiring ablation of eEF1A2 activity without clonal isolation.
HT29 cells are a well-characterized human colorectal adenocarcinoma cell line exhibiting epithelial morphology, originally isolated from a primary tumor of a 44-year-old Caucasian female. This cell line is extensively employed as an in vitro model for colorectal cancer research, particularly for investigating intestinal epithelial biology, differentiation, and tumor progression. HT29 cells retain key oncogenic mutations and signaling dependencies, making them a relevant system for studying colorectal cancer pathogenesis and evaluating therapeutic interventions.
EEF1A2 encodes eEF1A2, a translation elongation factor that facilitates the GTP-dependent binding of aminoacyl-tRNAs to the ribosomal A-site during protein synthesis. Beyond its canonical role in translation elongation, eEF1A2 exhibits moonlighting functions including actin filament bundling and inhibition of apoptosis. Expression of EEF1A2 is transcriptionally activated by MYC and E2F transcription factors downstream of mTORC1 and growth factor signaling, while the Wnt pathway also modulates its levels. The encoded protein interacts with ribosome subunits, aminoacyl-tRNAs, GTP, actin, PP2A, and PTEN. Knockout of EEF1A2 disrupts global protein synthesis and specifically reduces translation of pro-survival proteins such as Bcl-2 and XIAP, leading to diminished proliferation and enhanced apoptotic susceptibility. Key signaling nodes involving mTOR, EEF2K, and EEF2 converge on eEF1A2-mediated translational control, highlighting its central role in anabolic signaling.
In the HT29 colorectal adenocarcinoma background, disruption of EEF1A2 abrogates eEF1A2-driven translation elongation, impairing the synthesis of oncogenic and pro-survival proteins that sustain the aggressive phenotype of colorectal cancer cells. This loss-of-function model recapitulates the dependency of HT29 cells on eEF1A2 for maintaining proliferation, survival, and cytoskeletal integrity. The resulting attenuation of global protein synthesis and selective reduction of Bcl-2 and XIAP expression promotes apoptosis, while altered actin dynamics potentially interfere with cell migration and invasion. Consequently, these EEF1A2 knockout polyclonal cells serve as a valuable tool for dissecting translation-dependent mechanisms underlying colorectal tumorigenesis.
Researchers can employ these EEF1A2 knockout HT29 polyclonal cells for a wide range of applications, including investigation of oncogene dependency in colorectal cancer, validation of eEF1A2 as a therapeutic target, and functional studies of translation elongation control. Standard assays include western blotting to confirm loss of eEF1A2 and downstream targets, RT-qPCR for transcriptional profiling, MTT and colony formation assays to assess proliferation, and Annexin V staining for apoptosis measurement. Additionally, polysome profiling can be utilized to evaluate translation efficiency, while immunofluorescence for actin enables cytoskeletal analysis. Xenograft tumor growth studies in immunocompromised mice may further explore in vivo tumorigenicity. For more detailed information or technical support, please contact Ascent Research.
